Advertisement

Topics

Shionogi, Sage to Partner on Developing Depression Drug in Three Asian Markets

06:07 EDT 14 Jun 2018 | Genetic Engineering News

Shionogi & Co. will partner with Sage Therapeutics to develop and commercialize Sage’s SAGE-217 to treat major depressive disorder (MDD) and other indications in Japan, Taiwan, and South Korea, through a collaboration that could generate up to $575 million-plus for Sage. The companies said their collaboration is aimed at speeding up development in key Asian markets for SAGE-217. Shionogi and Sage disclosed their Asian collaboration last night, a day after Sage announced plans to launch an additional Phase III placebo-controlled trial in the U.S. in MDD in the second half of this year, in addition to its ongoing trial of the drug in women with postpartum depression (PPD), now designated a pivotal trial. The new trial will assess the efficacy of two weeks of 20 mg or 30 mg SAGE-217 treatment compared to placebo in 450 patients with MDD, with four weeks of additional follow-up, Sage ...

Original Article: Shionogi, Sage to Partner on Developing Depression Drug in Three Asian Markets

NEXT ARTICLE

More From BioPortfolio on "Shionogi, Sage to Partner on Developing Depression Drug in Three Asian Markets"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...